Mindset Pharma Inc CEO James Lanthier and CSO Joseph Araujo tell Proactive that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company’s patent application number 17/387,845, titled, “Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
The drug discovery and development firm said included within this application are several drug candidates that it classifies as belonging to its ‘Family 1’, which are second-generation compounds with potential improvements compared to psilocybin in pharmacokinetics, effect size, safety, and manufacturing.
